Ranbaxy Laboratories, India’s largest drugmaker, has been accused by US regulators of falsifying test results for some of its generic drugs.
As a result, the country’s Food and Drug Administration (FDA) is halting any consideration of new drugs from a plant owned by the company.
But despite the alleged fraudulent data, regulators say they have no evidence that the drugs are dangerous, and recommends that patients continue taking them.
The FDA had previously banned the import of more than 30 of Ranbaxy’s generic drugs after quality problems were alleged at two of its factories.
According to regulators, a lengthy investigation found that the company did not properly test the shelf-life and other measures of its drugs, later lying about the results.
In one case, company officials refrigerated drugs undergoing testing then indicated they had been stored at room temperature.
However, the FDA’s deputy director, Douglas Throckmorton, said: “We’ve not uncovered any harm associated with Ranbaxy products currently marketed in the US. We feel comfortable leaving those products on the market at this time.”
Copyright Press Association 2009